Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Delphine Rea

Showing results (31-40 of 101) with videos related to

Pageof 11
Sort By:
Critical Reviews in Oncology/Hematology|December 5, 2017
Ponatinib in chronic myeloid leukemia (CML): Consensus on patient treatment and management from a European expert panelMartin C Müller, Francisco Cervantes, Henrik Hjorth-Hansen, et al.
Therapeutic Drug Monitoring|December 30, 2025
Development and Validation of a Simultaneous Quantification Method for 12 Targeted Therapies and 3 Active Metabolites in Human Plasma Using Liquid Chromatography-Tandem Mass Spectrometry: An Application to Therapeutic Drug Monitoring in Patients With Hematological MalignanciesNicolas Vignal, Marie Allard, Sofiane Fodil, et al.
Journal of Leukocyte Biology|February 8, 2006
Imatinib mesylate minimally affects bcr-abl+ and normal monocyte-derived dendritic cells but strongly inhibits T cell expansion despite reciprocal dendritic cell-T cell activationNicolas Boissel, Philippe Rousselot, Emmanuel Raffoux, et al.
Leukemia|May 22, 2026
From fatal disease to functional cure: 25 years of tyrosine kinase inhibition in chronic myeloid leukemiaAndreas Hochhaus, Moshe Talpaz, Giuseppe Saglio, et al.
American Journal of Hematology|August 19, 2015
Clinical features of pulmonary arterial hypertension in patients receiving dasatinibNeil P Shah, Nicola Wallis, Harrison W Farber, et al.
Haematologica|June 12, 2013
Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitorsFranck E Nicolini, H Jean Khoury, Luke Akard, et al.
American Journal of Hematology|May 20, 2016
Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034Neil P Shah, Philippe Rousselot, Charles Schiffer, et al.
Bulletin Du Cancer|December 13, 2023
[Optimizing the use of bosutinib in patients with chronic-phase chronic myeloid leukemia: Recommendations of a panel of experts from the Fi-LMC (French CML working group)]Delphine Rea, Emilie Cayssials, Aude Charbonnier, et al.
Cancer|October 10, 2013
Tolerability and efficacy of pegylated interferon-α-2a in combination with imatinib for patients with chronic-phase chronic myeloid leukemiaHyacinthe Johnson-Ansah, Joelle Guilhot, Philippe Rousselot, et al.
The European Respiratory Journal|November 2, 2016
Deterioration of pulmonary hypertension and pleural effusion with bosutinib following dasatinib lung toxicityMarianne Riou, Andrei Seferian, Laurent Savale, et al.
Pageof 11

Showing results (31-40 of 101) with videos related to

Sort By:
Pageof 11
Critical Reviews in Oncology/Hematology|December 5, 2017
Ponatinib in chronic myeloid leukemia (CML): Consensus on patient treatment and management from a European expert panelMartin C Müller, Francisco Cervantes, Henrik Hjorth-Hansen, et al.
Therapeutic Drug Monitoring|December 30, 2025
Development and Validation of a Simultaneous Quantification Method for 12 Targeted Therapies and 3 Active Metabolites in Human Plasma Using Liquid Chromatography-Tandem Mass Spectrometry: An Application to Therapeutic Drug Monitoring in Patients With Hematological MalignanciesNicolas Vignal, Marie Allard, Sofiane Fodil, et al.
Journal of Leukocyte Biology|February 8, 2006
Imatinib mesylate minimally affects bcr-abl+ and normal monocyte-derived dendritic cells but strongly inhibits T cell expansion despite reciprocal dendritic cell-T cell activationNicolas Boissel, Philippe Rousselot, Emmanuel Raffoux, et al.
Leukemia|May 22, 2026
From fatal disease to functional cure: 25 years of tyrosine kinase inhibition in chronic myeloid leukemiaAndreas Hochhaus, Moshe Talpaz, Giuseppe Saglio, et al.
American Journal of Hematology|August 19, 2015
Clinical features of pulmonary arterial hypertension in patients receiving dasatinibNeil P Shah, Nicola Wallis, Harrison W Farber, et al.
Haematologica|June 12, 2013
Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitorsFranck E Nicolini, H Jean Khoury, Luke Akard, et al.
American Journal of Hematology|May 20, 2016
Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034Neil P Shah, Philippe Rousselot, Charles Schiffer, et al.
Bulletin Du Cancer|December 13, 2023
[Optimizing the use of bosutinib in patients with chronic-phase chronic myeloid leukemia: Recommendations of a panel of experts from the Fi-LMC (French CML working group)]Delphine Rea, Emilie Cayssials, Aude Charbonnier, et al.
Cancer|October 10, 2013
Tolerability and efficacy of pegylated interferon-α-2a in combination with imatinib for patients with chronic-phase chronic myeloid leukemiaHyacinthe Johnson-Ansah, Joelle Guilhot, Philippe Rousselot, et al.
The European Respiratory Journal|November 2, 2016
Deterioration of pulmonary hypertension and pleural effusion with bosutinib following dasatinib lung toxicityMarianne Riou, Andrei Seferian, Laurent Savale, et al.
Pageof 11